ESR1 and metastatic neoplasm: Nevertheless, the women identified by ER/PR ‘unknown status’ had a particularly shorter median follow up and higher one-year mortality (p<0.0001), suggesting perhaps a more aggressive disease behavior and/or more advanced metastatic disease at diagnosis among the ER/PR unknown group.